WMWilliam J. Meilandt

William J. Meilandt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William J. Meilandt has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Hai Ngu

    Department of Pathology, Genentech Inc., South San Francisco, USA

    5 shared publications
  • Oded Foreman

    Department of Pathology, Genentech Inc., South San Francisco, USA

    5 shared publications
  • Amy Easton

    Department of Neuroscience, Genentech Inc., South San Francisco, USA

    4 shared publications
  • Brad A. Friedman

    Bioinformatics, Genentech, Inc., South San Francisco, California 94080

    3 shared publications
  • Guita Lalehzadeh

    Departments of Neuroscience, Genentech, Inc., South San Francisco, California 94080

    3 shared publications
  • Kimberly L. Stark

    Departments of Neuroscience, Genentech, Inc., South San Francisco, California 94080

    3 shared publications

Latest Publications

  • Open Access

    Intranigral injection of alpha-synuclein pre-formed fibrils leads to BBB compromise and bilateral dopaminergic neurodegeneration in A53T alpha-synuclein transgenic mice

    by Soumitra Ghosh, Han H. Lin, Sarah Chu, Hai Ngu, Nanzhi Zang, Renee Raman, Kimberly Stark, Oded Foreman, Somaye Hashemifar, Amy Easton, et al.


  • Open Access

    Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple Sclerosis

    by Ainhoa Etxeberria, Yun-An A. Shen, Stephen Vito, Sean M. Silverman, Jose Imperio, Guita Lalehzadeh, Allison L. Soung, Changchun Du, Luke Xie, Man Kin Choy, et al.

    Human genetics and preclinical studies have identified key contributions of TREM2 to several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically. Here, we characterize the activities of three TREM2 agonist antibodies in multiple mixed-sex mouse models of Alzheimer's disease (AD) pathology and remyelination. Receptor activation and downstream signaling are explored in vitro, and active dose ranges are determined in vivo based on pharmacodynamic responses from microglia. For mice bearing amyloid-β (Aβ) pathology (PS2APP) or combined Aβ and tau pathology (TauPS2APP), chronic TREM2 agonist antibody treatment had limited impact on microglia engagement with pathology, overall pathology burden, or downstream neuronal damage. For mice with demyelinating injuries triggered acutely with lysolecithin, TREM2 agonist antibodies unexpectedly disrupted injury resolution. Likewise, TREM2 agonist antibodies limited myelin recovery for mice experiencing chronic demyelination from cuprizone. We highlight the contributions of dose timing and frequency across models. These results introduce important considerations for future TREM2-targeting approaches.


  • Top Cited Papers

    Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology

    by Seung-Hye Lee, William J. Meilandt, Luke Xie, Vineela D. Gandham, Hai Ngu, Kai H. Barck, Mitchell G. Rezzonico, Jose Imperio, Guita Lalehzadeh, Melanie A. Huntley, et al.


  • Open Access

    Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model

    by William J. Meilandt, Hai Ngu, Alvin Gogineni, Guita Lalehzadeh, Seung-Hye Lee, Karpagam Srinivasan, Jose Imperio, Tiffany Wu, Martin Weber, Agatha J. Kruse, et al.

    TREM2is an Alzheimer's disease (AD) risk gene expressed in microglia. To study the role ofTrem2in a mouse model of β-amyloidosis, we compared PS2APP transgenic mice versus PS2APP mice lackingTrem2(PS2APP;Trem2ko) at ages ranging from 4 to 22 months. Microgliosis was impaired in PS2APP;Trem2komice, withTrem2-deficient microglia showing compromised expression of proliferation/Wnt-related genes and marked accumulation of ApoE. Plaque abundance was elevated in PS2APP;Trem2kofemales at 6–7 months; but by 12 or 19–22 months of age, it was notably diminished in female and male PS2APP;Trem2komice, respectively. Across all ages, plaque morphology was more diffuse in PS2APP;Trem2kobrains, and the Aβ42:Aβ40 ratio was elevated. The amount of soluble, fibrillar Aβ oligomers also increased in PS2APP;Trem2kohippocampi. Associated with these changes, axonal dystrophy was exacerbated from 6 to 7 months onward in PS2APP;Trem2komice, notwithstanding the reduced plaque load at later ages. PS2APP;Trem2komice also exhibited more dendritic spine loss around plaque and more neurofilament light chain in CSF. Thus, aggravated neuritic dystrophy is a more consistent outcome ofTrem2deficiency than amyloid plaque load, suggesting that the microglial packing of Aβ into dense plaque is an important neuroprotective activity.SIGNIFICANCE STATEMENTGenetic studies indicate thatTREM2gene mutations confer increased Alzheimer's disease (AD) risk. We studied the effects ofTrem2deletion in the PS2APP mouse AD model, in which overproduction of Aβ peptide leads to amyloid plaque formation and associated neuritic dystrophy. Interestingly, neuritic dystrophies were intensified in the brains ofTrem2-deficient mice, despite these mice displaying reduced plaque accumulation at later ages (12–22 months). Microglial clustering around plaques was impaired, plaques were more diffuse, and the Aβ42:Aβ40 ratio and amount of soluble, fibrillar Aβ oligomers were elevated inTrem2-deficient brains. These results suggest that the Trem2-dependent compaction of Aβ into dense plaques is a protective microglial activity, limiting the exposure of neurons to toxic Aβ species.


  • Open Access

    Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

    by William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji, et al.

    Background: Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclonal antibody that has been shown to bind to synthetic monomeric and aggregated Aβ in vitro; however, less is known about the binding characteristic in vivo. In this study, we evaluated the binding patterns of crenezumab to synthetic and native forms of Aβ both in vitro and in vivo. Methods: Crenezumab was used to immunoprecipitate Aβ from synthetic Aβ preparations or brain homogenates from a PS2APP mouse model of AD to determine the forms of Aβ that crenezumab interacts with. Following systemic dosing in PS2APP or nontransgenic control mice, immunohistochemistry was used to localize crenezumab and assess its relative distribution in the brain, compared with amyloid plaques and markers of neuritic dystrophies (BACE1; LAMP1). Pharmacodynamic correlations were performed to investigate the relationship between peripheral and central target engagement. Results: In vitro, crenezumab immunoprecipitated Aβ oligomers from both synthetic Aβ preparations and endogenous brain homogenates from PS2APP mice. In vivo studies in the PS2APP mouse showed that crenezumab localizes to regions surrounding the periphery of amyloid plaques in addition to the hippocampal mossy fibers. These regions around the plaques are reported to be enriched in oligomeric Aβ, actively incorporate soluble Aβ, and contribute to Aβ-induced neurotoxicity and axonal dystrophy. In addition, crenezumab did not appear to bind to the dense core region of plaques or vascular amyloid. Conclusions: Crenezumab binds to multiple forms of amyloid β (Aβ), particularly oligomeric forms, and localizes to brain areas rich in Aβ oligomers, including the halo around plaques and hippocampal mossy fibers, but not to vascular Aβ. These insights highlight a unique mechanism of action for crenezumab of engaging Aβ oligomers.


  • Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease

    by Claire E. Le Pichon, William J. Meilandt, Sara Dominguez, Hilda Solanoy, Han Lin, Hai Ngu, Alvin Gogineni, Arundhati Sengupta Ghosh, Zhiyu Jiang, Seung-Hye Lee, et al.

    Blocking dual leucine zipper kinase slows disease progression in animal models of ALS and Alzheimer’s disease.